

Docket No. JAB-1267

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Embrechts et al.

Serial No.: 09/403,056

Art Unit: 1615

Filed

: October 13, 1999

Examiner: G.S. Kishore

For

7.2

: COMPOSITIONS

CONTAINING AN ANTIFUNGAL

AND Α

PHOSPHOLIPID

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Michele G. Mangini (Name of applicant, assignee, or Registered Representative)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Supplemental to the Information Disclosure Statement filed January 5, 2004, and pursuant to 37 C.F.R. §1.56, and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

\square In accordance with §1.129(a), this Information
Disclosure Statement is being filed in connection with \square the
first or _second After Final Submission, therefore:
Statement in Accordance with §1.97(e)
(attached); or
Please charge Deposit Account No. 10-
0750/ / the fee of $$180.00$ as set forth
in §1.17(p).

In accordance with §1.97(c), this Information

Disclosure Statement is being filed after the period set forth

in §1.97(b) above but before the mailing date of either a Final

Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of: Statement in Accordance with §1.97(e) (attached); or Please charge Deposit Account No. 10-/ the fee of \$180.00 as set forth §1.17(p). in In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p). X Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith. Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT: \Box In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith. If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Copies of only foreign patent documents and non-
patent literature are enclosed in accordance with 37 CFR 1.98
(a)(2). (The U.S. patents and each U.S. patent application
publication listed on the attached Form PTO-1449 are not
enclosed because this U.S. patent application was filed after
June 30, 2003 or this international application has entered the
national stage under 35 USC §371 after June 30, 2003 (see USPTO
waiver of requirement under 37 CFR 1.98 (a)(2)(i).
There are no listed references which are not in the
English language.
The relevance of those listed references which are
not in the English language is as follows:
Attached is a copy of a search report from related
PCT Patent Application No. PCT/EP98/02143 (Atty. Docket JAB-
1267 PCT) and related EPO Patent Application No. EP 97201101
(Atty. Docket JAB-1202 EPO), which are listed on the attached
Submission Under MPEP 609 D.
Attached are copies of search report(s) from
corresponding patent application(s), which are listed on the
attached Submission Under MPEP 609 D.
Attached are the following non-published pending
patent applications which may be deemed relevant, which are
listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/JAB1267/MGM. This form is submitted in triplicate.


Respectfully submitted,

Michele G. Mangini

Reg. No. 36,806

Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-2810 DATED: 26 January 2004



Page 1 of 1

Application Number	09/403,056
Filing Date	October 13, 1999
First Named Inventor	Embrechts et al.
Group Art Unit	1615
Examiner Name	Kishore, G.S.
Attorney Docket Number	JAB-1267

•			ENT DOCUMENTS	U.S. PAT		
			U.S. Patent Document			
	Pages, Columns, Lines, where relevant passages or relevant figures appear	Kind Code ² (if known)	Number	Name of Patentee or Applicant of Cited Document	Cite No.1	Examiner Initials
0~	MA					
CEIVER				_	· 1	
3 0	JAN					
3 0 ₂₀₀₄	TECHO					
D 10	· CENTA					
R 1600/2900					•	
, , , , , , , , , , , , , , , , , , , ,						

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Name of Patentee or Applicant of Cited Document	Office ³	Patent Docun	KindCode ⁵	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
						·	
			-				
		OTHER PRIOR ART - I	NON PATEN	T LITERATU	JRE DOCUMEN	ITS	<u> </u>
Examiner 's Initials*	Examiner Cite No.1 Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				g, etc.), date, page(s),	T²	
		PCT Search Report dated August 6, 1	998 for Seria	I No. PCT/EI	P98/02143 (Atty	/. Docket JAB-1267 PCT)	
		European Search Report dated Nove EPO)	ember 3, 199	7 for Serial	No. EP 97201	101 (Atty. Docket JAB-1202	

Examiner		Date		
Signature	<u> </u>	Considered		

LACI 2 8 2005

Useler the Paperwork Reduction Act of 1995, no persons are required to respond to

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute or form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 1

a collection of information unless it displays a	a valid OMB control number.
Application Number	09/403,056
Filing Date	October 13, 1999
First Named Inventor	Embrechts et al.
Group Art Unit	1615
Examiner Name	Kishore, G.S.
Attorney Docket Number	JAB-1267

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
		Arlettte, J., et al., Ketoconazole shampoo in seborrheic dermatitis, Can. J. Dermatol, 3, (1991) 175-180	
		Degreef, H. Jacobs, P.H., Rosenberg, E.W. & Shuster, S (eds.) Ketoconazole in Seborrhoeic dermatitis and dandruff: a review, Manchester: ADIS Press International Limited, (1989), pp. 1-62	
		JAN	9
		Ph	30 40
		TECH CENT	
		V5/1/	EH 160
,			

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.